Abstract：
UNASSIGNED: Patients with inborn errors of immunity (IEI) are predisposed to severe recurrent/chronic infections, and often require hospitalization, resulting in substantial burden to patients/healthcare systems. While immunoglobulin replacement therapies (IgRTs) are the standard first-line treatment for most forms of IEI, limited real-world data exist regarding clinical characteristics and treatment costs for patients with IEI initiating such treatment. This retrospective analysis examined infection and treatment characteristics in US patients with IEI initiating IgRT with immune globulin infusion (human), 10% (IG10%). Healthcare resource utilization (HCRU) and associated costs before and after treatment initiation were compared. Additionally, the impact of COVID-19 on infection diagnoses was evaluated.
UNASSIGNED: Patients with IEI initiating IG10% between July 2012 and August 2019 were selected from Merative MarketScan Databases using diagnosis/prescription codes. Patients were followed 6 months before and after first IG10% claim date. Demographic and clinical characteristics were described. Treatment characteristics and HCRU before and after IG10% initiation were compared. Infection diagnoses during 2020 and 2019 (March-December) were compared.
UNASSIGNED: The study included 1,497 patients with IEI diagnoses (mean age = 43.4 years) initiating IG10%, with frequently reported comorbidities like asthma (32.1%). Following IG10% initiation, fewer severe infection diagnoses (11.6% vs 19.9%), fewer infection-related inpatient (10.8% vs 19.5%) and outpatient services (71.6% vs 79.9%), and lower infection-related total healthcare costs ($7,849 vs $13,995; p < 0.001)-driven by lower inpatient costs ($2,746 vs $9,900)-were observed than before. Fewer patients had infection diagnoses during COVID-19 (22.8%) than the prior year (31.2%).
UNASSIGNED: Patients with IEI are susceptible to severe infections leading to high disease burden and treatment costs. Following IG10% initiation, we observed fewer infections, lower infection-related treatment costs, and shift in care (inpatient to outpatient) leading to significant cost savings. Among patients with IEI, 27% fewer infection diagnoses were observed during the early COVID-19 lockdown period than the prior year.
Some people are born with inborn errors of immunity, or IEI. This study included 1,497 people with IEI who recently started taking a drug called immunoglobulin therapy. Before taking this drug, the participants got infections easily, were hospitalized often, and had to take other costly medicines. After starting this drug, they had fewer infections and could be treated at the doctor’s office. They had fewer infections during the COVID-19 pandemic than before the pandemic.
UNASSIGNED: Patients with IEI initiating IG10% between July 2012 and August 2019 were selected from Merative MarketScan Databases using diagnosis/prescription codes. Patients were followed 6 months before and after first IG10% claim date. Demographic and clinical characteristics were described. Treatment characteristics and HCRU before and after IG10% initiation were compared. Infection diagnoses during 2020 and 2019 (March-December) were compared.
UNASSIGNED: The study included 1,497 patients with IEI diagnoses (mean age = 43.4 years) initiating IG10%, with frequently reported comorbidities like asthma (32.1%). Following IG10% initiation, fewer severe infection diagnoses (11.6% vs 19.9%), fewer infection-related inpatient (10.8% vs 19.5%) and outpatient services (71.6% vs 79.9%), and lower infection-related total healthcare costs ($7,849 vs $13,995; p < 0.001)-driven by lower inpatient costs ($2,746 vs $9,900)-were observed than before. Fewer patients had infection diagnoses during COVID-19 (22.8%) than the prior year (31.2%).
UNASSIGNED: Patients with IEI are susceptible to severe infections leading to high disease burden and treatment costs. Following IG10% initiation, we observed fewer infections, lower infection-related treatment costs, and shift in care (inpatient to outpatient) leading to significant cost savings. Among patients with IEI, 27% fewer infection diagnoses were observed during the early COVID-19 lockdown period than the prior year.
Some people are born with inborn errors of immunity, or IEI. This study included 1,497 people with IEI who recently started taking a drug called immunoglobulin therapy. Before taking this drug, the participants got infections easily, were hospitalized often, and had to take other costly medicines. After starting this drug, they had fewer infections and could be treated at the doctor’s office. They had fewer infections during the COVID-19 pandemic than before the pandemic.
摘要：
目的：患有先天性免疫错误（IEI）的患者易患严重的复发性/慢性感染，经常需要住院治疗，给患者/医疗保健系统带来沉重负担。虽然免疫球蛋白替代疗法（IgRTs）是大多数IEI形式的标准一线治疗，关于开始IEI治疗的患者的临床特征和治疗费用的实际数据有限.这项回顾性分析检查了使用免疫球蛋白输注（人）启动IgRT的IEI美国患者的感染和治疗特征，10%(IG10%)。比较了治疗开始前后的医疗资源利用率（HCRU）和相关成本。此外,评估了COVID-19对感染诊断的影响.方法：在2012年7月至2019年8月期间，使用诊断/处方代码从Merative®MarketScan®数据库中选择IEI起始IG10%的患者。在第一个IG10%索赔日期之前和之后6个月对患者进行随访。描述了人口统计学和临床特征。比较IG10%起始前后的治疗特征和HCRU。比较了2020年和2019年（3月至12月）期间的感染诊断。结果：该研究包括1,497例IEI诊断患者（平均年龄=43.4岁），开始IG10％，经常报告有哮喘等合并症(32.1%)。IG10%启动后,更少的严重感染诊断（11.6％vs19.9％），与感染相关的住院患者(10.8%对19.5%)和门诊服务(71.6%对79.9%)减少，与感染相关的总医疗费用较低(7,849美元对13,995美元;P<0.001)-由住院费用较低(2,746美元对9,900美元)驱动-观察到比以前更低。在COVID-19期间诊断为感染的患者（22.8%）比上一年（31.2%）少。结论:IEI患者易患严重感染,导致疾病负担和治疗费用高。IG10%启动后,我们观察到更少的感染，降低感染相关治疗费用，和护理转移(住院到门诊)，导致显著的成本节约。在IEI患者中，在COVID-19早期封锁期间，发现的感染诊断比上一年减少了27%。
有些人天生就有免疫错误，或IEI。这项研究包括1,497名IEI患者，他们最近开始服用一种称为免疫球蛋白疗法的药物。在服用这种药物之前，参与者很容易感染，经常住院，不得不服用其他昂贵的药物。开始服用这种药物后，他们感染较少，可以在医生办公室接受治疗。在COVID-19大流行期间，他们的感染人数少于大流行前。
有些人天生就有免疫错误，或IEI。这项研究包括1,497名IEI患者，他们最近开始服用一种称为免疫球蛋白疗法的药物。在服用这种药物之前，参与者很容易感染，经常住院，不得不服用其他昂贵的药物。开始服用这种药物后，他们感染较少，可以在医生办公室接受治疗。在COVID-19大流行期间，他们的感染人数少于大流行前。
